ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ BẰNG TESTOSTERONE THAY THẾ TRÊN BỆNH NHÂN SUY SINH DỤC THỨ PHÁT TẠI BỆNH VIỆN TRƯỜNG ĐẠI HỌC Y DƯỢC CẦN THƠ NĂM 2023 - 2024

Abstract

Background: Male hypogonadism is defined by a deficiency in testosterone production and impaired spermatogenesis in the testes, which is associated with aging and metabolic disorders such as diabetes and hypertension. Timely identification and appropriate management of the condition may enhance patients' quality of life. Among available options, testosterone replacement, especially the 1% gel formulation has been shown to be both effective and well-tolerated. Objectives: To investigate the clinical and paraclinical characteristics of patients with secondary hypogonadism and evaluate the treatment outcomes of testosterone replacement therapy in secondary hypogonadism patients at Can Tho University of Medicine and Pharmacy. Materials and methods: A case series study was conducted on 37 male patients diagnosed with secondary hypogonadism who were prescribed testosterone replacement therapy from November 2023 to November 2024 at Can Tho University of Medicine and Pharmacy Hospital. Results: In 37 men, most patients were aged 40-60 years, 3 months of 1% testosterone gel significantly elevated mean total testosterone from 10.01 ± 0.6 to 14.85 ± 0.3 nmol/L (p < 0.001). The prevalence of erectile dysfunction decreased significantly, and clinical symptoms (ADAM questionnaire) showed marked improvement. Mild side effects occurred in 5.9% of cases without treatment discontinuation. Conclusion: Testosterone replacement therapy using 1% gel is an effective and well-tolerated treatment option for secondary hypogonadism.